Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Combe

Showing results (131-140 of 160) with videos related to

Pageof 16
Sort By:
Arthritis Research & Therapy|January 22, 2020
Reduced progression of bone erosion in cytomegalovirus seropositive rheumatoid arthritis patientsB Rauwel, Y Degboé, D Nigon, et al.
Annals of the Rheumatic Diseases|June 12, 1999
Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single componentsM Dougados, B Combe, A Cantagrel, et al.
Annals of the Rheumatic Diseases|April 12, 2006
Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparisonB Combe, C Codreanu, U Fiocco, et al.
Annals of the Rheumatic Diseases|March 17, 2009
Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across EuropeP Emery, R Van Vollenhoven, M Ostergaard, et al.
Arthritis Care & Research|June 12, 2013
Safety of surgery after rituximab therapy in 133 patients with rheumatoid arthritis: data from the autoimmunity and rituximab registryS Godot, J-E Gottenberg, S Paternotte, et al.
Annals of the Rheumatic Diseases|September 17, 2008
Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year studyB Combe, C Codreanu, U Fiocco, et al.
Annals of the Rheumatic Diseases|May 8, 2010
Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritisR Knevel, M Schoels, T W J Huizinga, et al.
Annals of the Rheumatic Diseases|July 5, 2005
Clinical practice decision tree for the choice of the first disease modifying antirheumatic drug for very early rheumatoid arthritis: a 2004 proposal of the French Society of RheumatologyX Le Loët, J M Berthelot, A Cantagrel, et al.
Annals of the Rheumatic Diseases|June 30, 2000
Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritisJ S Smolen, F C Breedveld, G R Burmester, et al.
Arthritis and Rheumatism|May 28, 2010
Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registryJ-E Gottenberg, P Ravaud, T Bardin, et al.
Pageof 16

Showing results (131-140 of 160) with videos related to

Sort By:
Pageof 16
Arthritis Research & Therapy|January 22, 2020
Reduced progression of bone erosion in cytomegalovirus seropositive rheumatoid arthritis patientsB Rauwel, Y Degboé, D Nigon, et al.
Annals of the Rheumatic Diseases|June 12, 1999
Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single componentsM Dougados, B Combe, A Cantagrel, et al.
Annals of the Rheumatic Diseases|April 12, 2006
Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparisonB Combe, C Codreanu, U Fiocco, et al.
Annals of the Rheumatic Diseases|March 17, 2009
Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across EuropeP Emery, R Van Vollenhoven, M Ostergaard, et al.
Arthritis Care & Research|June 12, 2013
Safety of surgery after rituximab therapy in 133 patients with rheumatoid arthritis: data from the autoimmunity and rituximab registryS Godot, J-E Gottenberg, S Paternotte, et al.
Annals of the Rheumatic Diseases|September 17, 2008
Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year studyB Combe, C Codreanu, U Fiocco, et al.
Annals of the Rheumatic Diseases|May 8, 2010
Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritisR Knevel, M Schoels, T W J Huizinga, et al.
Annals of the Rheumatic Diseases|July 5, 2005
Clinical practice decision tree for the choice of the first disease modifying antirheumatic drug for very early rheumatoid arthritis: a 2004 proposal of the French Society of RheumatologyX Le Loët, J M Berthelot, A Cantagrel, et al.
Annals of the Rheumatic Diseases|June 30, 2000
Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritisJ S Smolen, F C Breedveld, G R Burmester, et al.
Arthritis and Rheumatism|May 28, 2010
Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registryJ-E Gottenberg, P Ravaud, T Bardin, et al.
Pageof 16